Schedule 13G ownership disclosure

ALIGOS THERAPEUTICS INC

Security class unavailable · CUSIP: 01626L105

Event date: 2021-12-31

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
2,419,613
Percent of class
5.7000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001274173-22-000082
Form type
SC 13G
Filer
Aligos Therapeutics, Inc.
CIK
CIK 1799448
Filed
Feb 14, 2022
Reporting period
Dec 31, 2021
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub